PriceSeer_data/news_data/DHR_news.csv

title,source,date,link,content
Danaher Corporation (DHR) Opinions on Recent Stock Slump and Strategic Partnerships,Nasdaq,"Jul 17, 2025",https://www.nasdaq.com/articles/danaher-corporation-dhr-opinions-recent-stock-slump-and-strategic-partnerships,"Recent discussions on X about Danaher Corporation (NYSE: DHR) have centered around the company's stock performance and strategic partnerships. Many users have noted a recent slump in the stock price, with some highlighting it reaching a five-week low, reflecting broader market concerns or sector-specific challenges. There’s also buzz about the company's innovative moves, particularly a new collaboration aimed at advancing precision medicine diagnostics.

Additionally, sentiment on X includes optimism about Danaher’s long-term potential, with several posts praising its historical growth and business model rooted in continuous improvement. Some discussions point to analyst upgrades and raised price targets as reasons for renewed interest. The upcoming quarterlyearnings callis another focal point, with anticipation building around how the company will address recent trends.

Note: This discussion summary was generated from an AI condensation of post data.

Danaher Corporation Congressional Stock Trading

Members of Congress have traded $DHR stock 12 times in the past 6 months. Of those trades, 2 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $DHR stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Danaher Corporation Insider Trading Activity

Danaher Corporation insiders have traded $DHR stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:

STEVEN M RALES (Chairman) has made 0 purchases and 8 sales selling 1,250,000 shares for an estimated $245,919,390 .

. CHRISTOPHER PAUL RILEY (Executive Vice President) has made 0 purchases and 2 sales selling 15,805 shares for an estimated $3,129,424 .

. BRIAN W ELLIS (Senior Vice President - GC) sold 5,700 shares for an estimated $1,277,541

ALAN G SPOON sold 550 shares for an estimated $113,553

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Danaher Corporation Hedge Fund Activity

We have seen 917 institutional investors add shares of Danaher Corporation stock to their portfolio, and 1,162 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Danaher Corporation Government Contracts

We have seen $179,899,622 of award payments to $DHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Danaher Corporation Analyst Ratings

Wall Street analysts have issued reports on $DHR in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Scotiabank issued a ""Sector Outperform"" rating on 07/11/2025

Barclays issued a ""Overweight"" rating on 06/24/2025

Guggenheim issued a ""Buy"" rating on 04/23/2025

Goldman Sachs issued a ""Buy"" rating on 04/23/2025

UBS issued a ""Buy"" rating on 04/23/2025

RBC Capital issued a ""Outperform"" rating on 04/23/2025

Baird issued a ""Outperform"" rating on 04/23/2025

To track analyst ratings and price targets for Danaher Corporation, check out Quiver Quantitative's $DHR forecast page.

Danaher Corporation Price Targets

Multiple analysts have issued price targets for $DHR recently. We have seen 14 analysts offer price targets for $DHR in the last 6 months, with a median target of $245.0.

Here are some recent targets:

Sung Ji Nam from Scotiabank set a target price of $275.0 on 07/11/2025

on 07/11/2025 Vijay Kumar from Evercore ISI Group set a target price of $226.0 on 07/08/2025

on 07/08/2025 Luke Sergott from Barclays set a target price of $225.0 on 06/24/2025

on 06/24/2025 Subbu Nambi from Guggenheim set a target price of $250.0 on 04/23/2025

on 04/23/2025 Dan Leonard from UBS set a target price of $240.0 on 04/23/2025

on 04/23/2025 Catherine Schulte from Baird set a target price of $225.0 on 04/23/2025

on 04/23/2025 Conor McNamara from RBC Capital set a target price of $250.0 on 04/23/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

This article was originally published on Quiver News , read the full story

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
3 Reasons to Avoid DHR and 1 Stock to Buy Instead,Yahoo Finance,"Jun 4, 2025",https://finance.yahoo.com/news/3-reasons-avoid-dhr-1-040255118.html,"Over the past six months, Danaher’s shares (currently trading at $193.08) have posted a disappointing 15.3% loss while the S&P 500 was down 1.8%. This may have investors wondering how to approach the situation.

Is there a buying opportunity in Danaher, or does it present a risk to your portfolio? See what our analysts have to say in our full research report, it’s free.

Why Is Danaher Not Exciting?

Even though the stock has become cheaper, we don't have much confidence in Danaher. Here are three reasons why you should be careful with DHR and a stock we'd rather own.

1. Core Business Falling Behind as Demand Declines

We can better understand Research Tools & Consumables companies by analyzing their organic revenue. This metric gives visibility into Danaher’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement.

Over the last two years, Danaher’s organic revenue averaged 4.7% year-on-year declines. This performance was underwhelming and implies it may need to improve its products, pricing, or go-to-market strategy. It also suggests Danaher might have to lean into acquisitions to grow, which isn’t ideal because M&A can be expensive and risky (integrations often disrupt focus).

Danaher Organic Revenue Growth

2. Shrinking Adjusted Operating Margin

Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.

Looking at the trend in its profitability, Danaher’s adjusted operating margin decreased by 4.3 percentage points over the last two years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. Its adjusted operating margin for the trailing 12 months was 28.5%.

Danaher Trailing 12-Month Operating Margin (Non-GAAP)

3. Free Cash Flow Margin Dropping

Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.

As you can see below, Danaher’s margin dropped by 6.2 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. Danaher’s free cash flow margin for the trailing 12 months was 20.6%."
Is Danaher Corporation (DHR) the Best Medical Device Stock to Buy Now?,Yahoo Finance,"May 9, 2025",https://finance.yahoo.com/news/danaher-corporation-dhr-best-medical-103247174.html,"We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other best medical device stocks to buy now.

Trump’s Tariffs Are Dividing the Medical Community

On April 16, CNBC reported that Trump’s tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president’s newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back.

The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation:

“MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.”

Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined:

“The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.”

READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds.

Pricing Complexity in the Medical Device Sector

President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump’s second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices."
"Danaher (DHR) Stock Trades Up, Here Is Why",Yahoo Finance,"Apr 22, 2025",https://finance.yahoo.com/news/danaher-dhr-stock-trades-why-182213895.html,"What Happened?

Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 6.6% in the afternoon session after the company reported impressive first quarter 2025 results, which beat analysts' organic revenue and EPS expectations. Revenue was flat year-over-year on a core basis, which masked a 7% gain in biotech and a modest decline in life sciences, revealing the uneven recovery across business lines. Looking ahead, sales guidance for the next quarter was ahead, while full year EPS guidance also beat Wall Street's expectations. Overall, we think this was a solid quarter with some key areas of upside.

The shares closed the day at $191.89, up 3.8% from previous close.

Is now the time to buy Danaher? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Danaher’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

Danaher is down 16.4% since the beginning of the year, and at $192.07 per share, it is trading 31.6% below its 52-week high of $280.76 from July 2024. Investors who bought $1,000 worth of Danaher’s shares 5 years ago would now be looking at an investment worth $1,199.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link."
Why Danaher Corporation (DHR) is the Best Medical Device Stock to Buy,Yahoo Finance,"Feb 12, 2025",https://finance.yahoo.com/news/why-danaher-corporation-dhr-best-142103457.html,"We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other best medical device stocks to buy right now.

Overview of the Medical Devices Sector

According to a report by Mordor Intelligence, the medical devices market has a size of $681.57 billion as of 2025. The massive industry is expected to grow at a compound annual growth rate of 6.99% between 2025 and 2030, reaching a market size of $955.49 billion by the end of the forecast period.

This significant growth can be attributed to various megatrends in the healthcare sector. The aging population worldwide is one of the primary factors affecting the industry. This is especially true in high-income countries such as the US, as around 17% of the country’s population is 65 or older as of 2023. This is causing an increase in the prevalence of chronic diseases, which is ultimately driving the demand for medical devices.

This demand is anticipated to continue growing in the coming decades. According to statistics by the United Nations, the number of people aged 65 or older is anticipated to represent around 16% of the world’s population by 2050, which translates to around 1.5 billion people worldwide. This demographic shift is anticipated to materialize especially prominently in regions such as Europe and North America, where the population of 65 or older is expected to reach 26.9% by 2050.

READ ALSO: 12 Best Hair Care Stocks to Buy According to Hedge Funds and 10 Best Furniture Stocks to Buy Right Now.

Continued Growth in the US Medical Device Manufacturing Sector

In addition, technological advancements such as the increasing use of AI, predictive analysis, and advanced algorithms are metamorphosing the healthcare technology industry. While North America is the largest medical device market, Asia-Pacific is the fastest growing.

Another report by Grand View Research estimates that the market size of medical device manufacturers in the US is around $256.2 billion as of 2024. It is expected to grow at a compound annual growth rate of 5.9% between 2025 and 2030. The primary reasons behind this growth include the increasing geriatric population, the growing number of road and sports accidents, the expanding geographic reach of the key players in the market, and the rising adoption of minimally invasive procedures in the industry.

The Future of the Healthcare Industry in the US

According to McKinsey, the healthcare industry is expected to continually undergo a shift in growth dynamics. Health services and technology (HST) revenue pools are anticipated to grow at a compound annual growth rate of 8% between 2023 and 2028, supported by double-digit growth in software platforms and advanced data and analytics. The sales of innovative technologies such as generative AI to payers and providers are further supporting this growth."
"At US$238, Is Danaher Corporation (NYSE:DHR) Worth Looking At Closely?",Simply Wall Street,"Jan 10, 2025",https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/at-us238-is-danaher-corporation-nysedhr-worth-looking-at-clo,"Let's talk about the popular Danaher Corporation ( ). The company's shares received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$274 at one point, and dropping to the lows of US$226. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Danaher's current trading price of US$238 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Danaher’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Advertisement

What's The Opportunity In Danaher?

According to our valuation model, Danaher seems to be fairly priced at around 16.46% above our intrinsic value, which means if you buy Danaher today, you’d be paying a relatively fair price for it. And if you believe that the stock is really worth $204.45, there’s only an insignificant downside when the price falls to its real value. In addition to this, Danaher has a low beta, which suggests its share price is less volatile than the wider market.

Can we expect growth from Danaher?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 51% over the next couple of years, the future seems bright for Danaher. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? It seems like the market has already priced in DHR’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

Are you a potential investor? If you’ve been keeping an eye on DHR, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

So while earnings quality is important, it's equally important to consider the risks facing Danaher at this point in time. Case in point: We've spotted you should be aware of.

If you are no longer interested in Danaher, you can use our free platform to see our list of over

New: Manage All Your Stock Portfolios in One Place We've created the ultimate portfolio companion for stock investors, and it's free. • Connect an unlimited number of Portfolios and see your total in one currency

• Be alerted to new Warning Signs or Risks via email or mobile

• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.



This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
DHR Stock Price and Chart — NYSE:DHR,TradingView,"Jul 21, 2017",https://www.tradingview.com/symbols/NYSE-DHR/,"Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Show more"
$DHR stock is up 2% today. Here's what we see in our data.,Quiver Quantitative,3 weeks ago,https://www.quiverquant.com/news/%24DHR+stock+is+up+2%25+today.+Here%27s+what+we+see+in+our+data.,"$DHR stock has now risen 2% today, according to our price data from Polygon. There has been approximately $626,890,023 of trading volume.

$DHR Insider Trading Activity

Here is what we see in our data on $DHR (you can track the company live on Quiver's $DHR stock page ):

$DHR insiders have traded $DHR stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:

STEVEN M RALES (Chairman) has made 0 purchases and 8 sales selling 1,250,000 shares for an estimated $245,919,390 .

. CHRISTOPHER PAUL RILEY (Executive Vice President) has made 0 purchases and 2 sales selling 15,805 shares for an estimated $3,129,424 .

. TERI LIST sold 2,778 shares for an estimated $586,319

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$DHR Hedge Fund Activity

We have seen 950 institutional investors add shares of $DHR stock to their portfolio, and 1,061 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Receive $DHR Data Alerts Sign Up

$DHR Government Contracts

We have seen $110,320,971 of award payments to $DHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$DHR Congressional Stock Trading

Members of Congress have traded $DHR stock 8 times in the past 6 months. Of those trades, 3 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $DHR stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$DHR Analyst Ratings

Wall Street analysts have issued reports on $DHR in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Evercore ISI Group issued a ""Outperform"" rating on 10/07/2025

B of A Securities issued a ""Buy"" rating on 09/22/2025

UBS issued a ""Buy"" rating on 07/23/2025

Baird issued a ""Outperform"" rating on 07/23/2025

Guggenheim issued a ""Buy"" rating on 07/23/2025

Scotiabank issued a ""Sector Outperform"" rating on 07/11/2025

Barclays issued a ""Overweight"" rating on 06/24/2025

To track analyst ratings and price targets for $DHR, check out Quiver Quantitative's $DHR forecast page.

$DHR Price Targets

Multiple analysts have issued price targets for $DHR recently. We have seen 13 analysts offer price targets for $DHR in the last 6 months, with a median target of $230.0.

Here are some recent targets:

Ed Ridley-Day from Rothschild & Co set a target price of $220.0 on 10/08/2025

on 10/08/2025 Vijay Kumar from Evercore ISI Group set a target price of $245.0 on 10/07/2025

on 10/07/2025 Derik De Bruin from B of A Securities set a target price of $220.0 on 09/22/2025

on 09/22/2025 Dan Leonard from UBS set a target price of $225.0 on 07/23/2025

on 07/23/2025 Catherine Schulte from Baird set a target price of $229.0 on 07/23/2025

on 07/23/2025 Subbu Nambi from Guggenheim set a target price of $250.0 on 07/23/2025

on 07/23/2025 Brandon Couillard from Wells Fargo set a target price of $205.0 on 07/23/2025

You can track data on $DHR on Quiver Quantitative.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies."
Here's Why Shares in Danaher Got Boosted Higher Today,The Motley Fool,3 weeks ago,https://www.fool.com/investing/2025/10/21/heres-why-shares-in-danaher-got-boosted-higher-tod/,"The company's third-quarter earnings pleased investors.

Shares in biotechnology, life sciences, and diagnostics company Danaher (DHR 0.35%) rose by as much as 12.9% in early morning trading today. The move follows a well-received third-quarter earnings report, which saw the company beat its own and the market's expectations.

What happened in Danaher's third quarter

Having forecast core revenue growth in the low-single-digit range and an adjusted operating profit margin of 25.5% for the third quarter on its second-quarter earnings call, management was pleased to announce core revenue growth of 3% and an adjusted operating profit margin of 27.9% for the third quarter.

Expand NYSE : DHR Danaher Today's Change ( -0.35 %) $ -0.73 Current Price $ 209.94 Key Data Points Market Cap $148B Day's Range $ 207.75 - $ 211.26 52wk Range $ 171.00 - $ 258.23 Volume 113 Avg Vol 4M Gross Margin 61.79 % Dividend Yield 0.01 %

Management put the outperformance down to ""DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid."" DBS refers to the Danaher Business System (a management system emphasizing continuous improvement). Danaher's bioprocessing business continues on a strong growth path, driven by increasing production and research into biologics, notably monoclonal antibodies.

As for the better-than-expected growth at Cepheid (its diagnostics segment), CEO Rainer Blair said, ""Customers began purchasing earlier than typical in preparation for the upcoming respiratory season,"" in other words, Danaher benefited from a pull-forward in revenue driven by the flu season.

What it means for investors

While a good set of results is always positive, the market may have overreacted to this news. Management's preliminary guidance for 2026 calls for core revenue growth of 3% to 6% (a pretty wide range at the best of times) and no more than high-single-digit earnings growth. That encompasses what the market was expecting before these earnings, with biotechnology offsetting modest growth in life sciences, and uncertainty around the diagnostics segment's exposure to China. That's fair enough, but with the stock trading at almost 29 times the estimated 2025 earnings, it might not be enough to take the stock significantly higher from here."
Jim Cramer Says “Danaher Gave Us the Quarter We’ve Been Looking For”,Yahoo Finance,2 weeks ago,https://finance.yahoo.com/news/jim-cramer-says-danaher-gave-132036738.html,"Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently highlighted. Discussing the post-earnings rally of the stock, Cramer remarked:

“Then there’s Danaher, DHR, the life sciences and diagnostic equipment company, which has been a huge disappointment for my Charitable Trust for so long. Not today, though. Today, Danaher gave us the quarter we’ve been looking for with a promise that next year could be even stronger, and that’s why the stock shot up nearly 6% today.”

A stock market data. Photo by Alesia Kozik on Pexels

Danaher Corporation (NYSE:DHR) designs and produces technologies, instruments, and consumables for biotechnology, life sciences, and diagnostics. Cramer mentioned the stock during the October 1 episode and said:

“Some of these healthcare stocks seem played out already to you, perhaps. I mean, Merck was up 7% just today. Charitable holding Danaher also leaped more than 7%. But these stocks have been down so long, they look up to me. I believe they’ve got a lot more upside before they run out of steam. My Charitable Trust owns Danaher, and it has been a huge disappointment. It needs to demonstrate it can capitalize off of all the new drug companies coming public right now, or it will go back to the 180s.”

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey."